Advertisement

Multiple Myeloma

FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

On February 22, the U.S. Food and Drug Administration (FDA) expanded the existing indication for lenalidomide 10 mg capsules to include use for patients with multiple myeloma...

Genomics/Genetics
Issues in Oncology

Payers Weigh the Implications of Multigene Testing Coverage

Innovation in precision medicine has introduced an amalgam of testing options, of which hereditary cancer panels—multigene tests—are a major component...

Neuroendocrine Tumors

Telotristat Ethyl: A Novel Therapy for Carcinoid Syndrome—Not a Panacea but a Step in the Right Direction

The multihumoral manifestations of neuroendocrine tumors include diarrhea, cutaneous flushing, wheezing, and right-sided valvular heart disease...


Advertisement

More Top Stories

Gastroesophageal Cancer

Ian Chau, MD, on Esophageal and Gastric Cancers: Systemic Agents and Options

Double Your Impact: Donate to the Conquer Cancer Foundation Today

If you’ve never given to the Conquer Cancer Foundation (CCF), now’s the time. An anonymous donor has generously offered to match—dollar for dollar—first-time gifts to CCF.

Funds raised through the challenge will be used to support CCF’s vital work, including funding clinical and translational...

Advertisement

Study Finds Cancer Mortality in Hispanics Varies Among Ethnic Groups

Although cancer is a leading cause of death among Hispanics, the burden of cancer mortality within Hispanic groups has not been well quantified. Now, a study by Pinheiro et al comparing the differences among Hispanic populations and cancer incidence has found that cancer mortality varies...

Thyroid Cancer
Survivorship

Dong Wook Shin, MD, DrPH, MBA, on Thyroid Cancer: Risk of Side Effects

Lymphoma

Liquid Biopsies Show Promise in Diffuse Large B-Cell Lymphoma

Technologic advances for detecting and analyzing cell-free circulating tumor DNA (ctDNA) from peripheral blood offer a precision method for monitoring diffuse large B-cell lymphoma (DLBCL). Although most patients with DLBCL are cured with initial therapy, those who are not cured have a poor...

Leukemia

Postinduction MRD Predicts Outcome From Transplantation in NPM1-Mutant AML

In an analysis of a French trial reported in the Journal of Clinical Oncology, Balsat et al found that postinduction minimal residual disease was predictive of outcome and benefit from allogeneic stem cell transplantation (ASCT) in patients with NPM1-mutant acute myeloid leukemia (AML). Nicolas...

Myeloablative vs Reduced-Intensity HCT for Acute Myeloid Leukemia and Myelodysplastic Syndromes

In a phase III trial reported in the Journal of Clinical Oncology, Scott et al found that myeloablative conditioning for allogeneic hematopoietic cell transplantation was associated with a reduced risk of relapse and a nonsignificant overall survival advantage vs reduced-intensity conditioning in...

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: Active Surveillance

Neuroendocrine Tumors

Telotristat Ethyl Reduces Frequency of Bowel Movements in Patients With Metastatic Neuroendocrine Tumors and Carcinoid Syndrome

In the phase III TELESTAR trial reported in the Journal of Clinical ­Oncology by Matthew H. Kulke, MD, of Dana-Farber Cancer Institute, and colleagues, telotristat ethyl, an investigational tryptophan hydroxylase inhibitor, significantly reduced the frequency of bowel movements in patients with...

Advertisement

FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

On February 22, the U.S. Food and Drug Administration (FDA) expanded the existing indication for lenalidomide (Revlimid) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant. The expanded indication makes...


click me